Esperion Therapeutics, Inc. (ESPR) Stock Price & Analysis
Esperion Therapeutics, Inc. (ESPR) fell 0.32% to USD 3.14 as of June 10, 2026 at 03:28 UTC, according to Nexqual real-time market data.
ESPR last closed at USD 3.15; the session ranged USD 3.14–3.15 on volume of 7,180,139 shares. Market capitalization is $809.16M, with a 52-week range of USD 0.95–4.18 (NGM). Source: Nexqual, June 10, 2026 at 03:28 UTC.
Key Statistics (as of June 10, 2026 at 03:28 UTC)
| Price | USD 3.14 |
|---|---|
| Change | ▼ 0.32% (down) |
| Previous Close | USD 3.15 |
| Open | USD 3.14 |
| Day Range | USD 3.14 – 3.15 |
| 52-Week Range | USD 0.95 – 4.18 |
| Volume | 7,180,139 shares |
| Market Cap | $809.16M |
| Exchange | NGM |
Technical Analysis (ESPR)
Nexqual's technical model rates ESPR "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 88.23 (overbought) |
| vs SMA50 | Above (USD 2.69) |
| MACD | 0.11 (positive) |
Analyst Ratings (ESPR)
Wall Street analysts rate ESPR "None" based on 4 analysts, with a mean price target of USD 3.19 (range USD 3.16–3.28), per Nexqual as of June 10, 2026 at 03:28 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 3.19 |
| High Target | USD 3.28 |
| Low Target | USD 3.16 |
| Buy / Hold / Sell | 0 / 6 / 0 |
Earnings (ESPR)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $76.60M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.1 vs est -0.03 ▼ miss |
| 2025-12-31 | USD 0.22 vs est 0.28 ▼ miss |
| 2025-09-30 | USD -0.16 vs est -0.08 ▼ miss |
| 2025-06-30 | USD -0.02 vs est -0.16 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financials & Fundamentals (ESPR)
| Total Revenue | $418.24M |
|---|---|
| Revenue Growth (YoY) | +23.20% |
| Gross Margin | +57.79% |
| Operating Margin | -8.22% |
| Profit Margin | -1.77% |
| Current Ratio | 1.53 |
| Total Cash | $156.16M |
| Total Debt | $543.81M |
| Free Cash Flow | $-49.71M |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Financial Health Score (ESPR)
Nexqual rates Esperion Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:28 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 58%, operating -8% |
| Balance Sheet | Mixed — $156M cash vs $544M debt |
| Cash Flow | Weak — FCF negative: -$50M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ESPR)
| Insider Ownership | +0.84% |
|---|---|
| Institutional Ownership | +70.01% |
| Shares Outstanding | 257.69M |
| Float | 255.24M |
| Short % of Float | +7.39% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
Leadership (ESPR)
Esperion Therapeutics, Inc. is led by Sheldon L. Koenig (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:28 UTC.
| President, CEO & Director | Sheldon L. Koenig (age 59) |
|---|---|
| Chief Financial Officer | Benjamin Halladay (age 39) |
| Associate Director of Corporate Communications | Tiffany Aldrich |
| Vice President of Drug Discovery of Early Pre-Clinical Development | Stephen Pinkosky |
Major Backers & Investors (ESPR)
Notable institutional backers of Esperion Therapeutics, Inc. include Wasatch Advisors LP, Two Seas Capital Lp, WASATCH FUNDS TRUST-Wasatch Small Cap Growth Fund, according to Nexqual as of June 10, 2026 at 03:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wasatch Advisors LP | 6.13% |
| Two Seas Capital Lp | 4.43% |
| WASATCH FUNDS TRUST-Wasatch Small Cap Growth Fund | 4.12% |
| Orbimed Advisors LLC. | 4.11% |
| Two Sigma Investments, LP | 3.67% |
| Marshall Wace LLP | 2.75% |
| Shaw D.E. & Co., Inc. | 2.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.65% |
| Vanguard Group | 8% |
| State Street | 3.66% |
Source: Nexqual, June 10, 2026 at 03:28 UTC.
From Esperion Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
- The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.
- Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
- It has license and collaboration agreements with Daiichi Sankyo Co.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HRTX | Heron Therapeutics, Inc. | USD 0.4 | ▼ 5.84% |
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 28.14 | ▼ 0.53% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| KYNB | Kyntra Bio, Inc. | USD 6.69 | ▼ 0.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:28 UTC. This page is informational and not investment advice.